L 163017

Drug Profile

L 163017

Latest Information Update: 24 Jan 2008

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antihypertensives; Heart failure therapies
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Angiotensin type 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure; Hypertension

Most Recent Events

  • 06 Aug 1998 No-Development-Reported for Heart failure in USA (Unknown route)
  • 06 Aug 1998 No-Development-Reported for Hypertension in USA (Unknown route)
  • 04 Mar 1996 A study in animals has been added to the Hypertension pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top